CA088-1005

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/​or Refractory Multiple Myeloma

What will happen during the trial?

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
147 patients (estimated)
Sponsors
Juno Therapeutics, a Bristol-Myers Squibb Company
Tags
CAR T Cell, GPRC5D
Trial Type
Treatment
Last Update
SparkCures ID
1795
NCT Identifier
NCT06121843

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.